Abstract
To get information on other effects of rhEPO than correction of RA we have run a controlled randomized study in young(100g) rats looking for following parameters: food intake(FI), weight gain(WG), growth(G), organ masses (heart, liver, spleen, kidney - corrected for body weight), blood pressure(BP), thrombocytes(T), and potassium (K). 20 animals were subtotally nephrectomized and received either 4 IU rhEPO sc/d or solvent for 4 weeks with free access to food(urea 21.5 mmol/l). 20 sham-operated pair fed and 20 ad lib fed animals with and without rhEPO respectively, served as controls(urea 5.9 mmol/l). Although RA could be prevented by rhEPO (Hct 51 vs 44%, p<0.05), it did neither affect FI nor WG,G,T and K. However, BP+was slightly increased in the rhEPO treated uremic animals(135±10 vs 121±7 mm Hg, p<0.05) as was the spleen weight whereas the other organ masses remained unaffected by rhEPO which could not prevent myocardial hypertrophy. Data suggest that treatment with rhEPO will not ameliorate uremia induced stunting and myocardial hypertrophy and usually leads to hypertension which must be regarded as the most serious side effect.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller-wiefel, D., Mehls, O., Scigalla, P. et al. 83 EFFECTS OF RECOMBINANT HUMAN ERYTHROPOIETIN (rhEPO) DURING CORRECTION OF RENAL ANEMIA (RA) IN EXPERIMENTAL UREMIA. Pediatr Res 24, 274 (1988). https://doi.org/10.1203/00006450-198808000-00109
Issue Date:
DOI: https://doi.org/10.1203/00006450-198808000-00109